索拉非尼联合用药在甲状腺未分化癌中的研究现状被引量：2

Research status on sorafenib combined medication in anaplastic thyroid cancer

导出

摘要甲状腺未分化癌是恶性程度最高的甲状腺癌。索拉非尼可通过多途径发挥抑癌作用,索拉非尼联合用药治疗甲状腺未分化癌显示出相对积极的结果,治疗效果明显优于单药。本文将对索拉非尼联合用药治疗甲状腺未分化癌的研究进展进行综述,以期能为甲状腺未分化癌的有效治疗提供参考依据。 Anaplastic thyroid cancer is the most malignant thyroid cancer. Sorafenib can exert anti-cancer effects through multiple channels. The combination of sorafenib in the treatment of anaplastic thyroid cancer has shown relatively positive results, and the therapeutic effect is significantly better than that of single drug. This article will review the research progress of sorafenib combination therapy for anaplastic thyroid cancer, in order to provide a reference for effective treatment of anaplastic thyroid cancer.

作者杨天乐徐丽莎符宇涛王姝婷唐任绮金欣 YANG Tian-le;XU Li-sha;FU Yu-tao;WANG Shu-ting;TANG Ren-qi;JIN Xin(Medical College,Shaoxing University,Shaoxing 312000,Zhejiang Province,China)

机构地区绍兴文理学院医学院

出处《中国临床药理学杂志》 CAS CSCD 北大核心 2021年第11期1459-1462,共4页 The Chinese Journal of Clinical Pharmacology

基金国家科技重大专项“十三五”计划课题资助项目(2018ZX10305410-410-007) 浙江省基础公益研究计划课题资助项目(LGF18H160014) 绍兴文理学院学生科研基金资助项目(医学院202018)。

关键词索拉非尼联合用药甲状腺未分化癌协同作用调节信号通路 sorafenib combined medication anaplastic thyroid cancer synergistic effect regulating signal pathway

分类号 R979.1 [医药卫生—药品]

引文网络
相关文献

参考文献1

1赵建龙,占辉,杨月,李文哲,王中辉,邱相君.索拉非尼的临床应用和药物相互作用[J].中国临床药理学杂志,2014,30(10):958-961. 被引量：6

二级参考文献34

1靳毅,刘巍.索拉非尼治疗非小细胞肺癌的临床研究进展[J].肿瘤,2010,30(9):795-797. 被引量：6
2Couchman L, Birch M, Ireland R, et al. An automated method forthe measurement of a range of tyrosine kinase inhibitors in humanplasma or serum using turbulent flow liquid chromatography - tan-dem mass spectrometry [ J ]. Anal Bioanal Chem, 2012, 403 :1685 -1695.
3Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview ofsorafenib, a multikinase inhibitor that targets both Raf and VEGFand PDGF receptor tyrosine kinase signaling[ J]. Mol Cancer Thery2008,7:3129 -3140.
4Takimoto CH, Awada A. Safety and anti - tumor activity of sor-afenib (Nexavar) in combination with other anti - cancer agents: areview of clinical trials[ J]. Cancer Chemother Pharmacol, 2008,61:535 -548.
5Brendel E,Ludwig M,Lathia C, et al. Pharmacokinetic results of aphase I trial of sorafenib in combination with dacarbazine in patientswith advanced solid tumors [ J ]. Cancer Chemother Pharmacol,2011,68:53 -61.
6Heinz WJ,Kahle K, Helle - Beyersdorf A,et al. High - perform-ance liquid chromatographic method for the determination of sor-afenib in human serum and peritoneal fluid [ J ] . Cancer ChemotherPharmacol, 2011,68:239 -245.
7Flaherty KT, Lathia C, Frye RF, et al. Interaction of sorafenib andcytochrome P450 isoenzymes in patients with advanced melanoma : aphase I/II pharmacokinetic interaction study[ J]. Cancer ChemotherPharmacol, 2011,68:1111 -1118.
8Kenny JR, Mukadam S, Zhang C, et al. Drug - drug interactionpotential of marketed oncology drugs ; in vitro assessment of time -dependent cytochrome P450 inhibition,reactive metabolite formationand drug - drug interaction prediction [ J ]. Pharm, Res, 2012,29 :1960 -1976.
9Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cellapoptosis in hepatocellular carcinoma model PLC/PftF/5 [ J ].Cancer Res, 2006,66: 11851 -11858.
10Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment ofrenal ceil carcinoma ; Final efficacy and safety results of the phaseIIItreatment approaches in renal cancer global evaluation trial [ J ].J Clin Oncol, 2009,27:3312 -3318.